Publication | Closed Access

Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia

Hematological MalignancyLymphoid NeoplasiaOncologyMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematologyPathologyCytometryNext Generation SequencingMolecular DiagnosticsMeasurable Residual DiseaseLaboratory MedicineRadiation OncologyMultiparameter Flow CytometryCancer ResearchHealth Sciences